Rapid-Acting Intramuscular Olanzapine + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Sep 1, 2009 → Apr 1, 2011
NCT ID
NCT00970281About Rapid-Acting Intramuscular Olanzapine + Placebo
Rapid-Acting Intramuscular Olanzapine + Placebo is a phase 3 stage product being developed by Eli Lilly for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00970281. Target conditions include Schizophrenia.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00970281 | Phase 3 | Completed |
Competing Products
20 competing products in Schizophrenia